The increase in the prevalence of diabetes is one of the major factors driving the growth of point-of-care glucose testing market in the North American region. According to the National Diabetes Statistics Report for 2020, around 34.2 million, or 10.5% of the U.S. population, have diabetes. An estimated 26.8 million people or 10.2% of the population had been diagnosed with diabetes. Moreover, as per the stats from the Public Agency from Canada, an estimated 3.6 million Canadians had diabetes, representing 9.3% of the population in 2020. Diabetes is more common in older Canadians, with approximately 28% of Canadians over the age of 65 living with the condition.

Request Sample PDF here @ https://univdatos.com/report/point-of-care-glucose-testing-market/get-a-free-sample-form.php?product_id=36290

Further,the North AmericaPoint-of-Care Glucose Testing Marketis expected to grow at a strong CAGR of 3% during the forecast period (2022-2028).North America held a dominant share of the market in 2021. Advances in technology have led to the development of more accurate and efficient glucose testing devices, which are easier to use and provide faster results. This has further increased the demand for these devices in North America. Apart from this, the region has the presence of several key players, such as Abbott, Nova Biomedical, and Prodigy Diabetes Care, LLC. This has increased the availability of glucose testing products, thereby contributing to the revenue generation of the regional market. In addition, higher healthcare expenditure by governments on diabetes management is one of the factors responsible for regional market growth.

Based on product, the market is segmented into accu check aviva meter, onetouch verio flex, i-STAT, freestyle lite, Bayer contour blood glucose monitoring system, true metrix, accu-chek inform II, statStrip, and others. The accu-chek inform II category held a significant share of the market in 2021. The accu-chek inform II is offered by Roche and provides high-accuracy results with proven repeatability and reproducibility. Moreover, the accu-chek inform II solution brings ISO15197:2013 safety standards to bedside glucose testing and helps ensure safety for patients and users. Thus, these factors are driving segmental growth.

Ask for Customization @ https://univdatos.com/report/point-of-care-glucose-testing-market/get-a-free-sample-form.php?product_id=36290

By end user, the market is categorized into hospitals, home settings, and others. The home care settings is anticipated to register high CAGR during the forecast period. The home-based glucose monitoring is revolutionized by the self-monitoring of blood glucose and is the most widely used method of short-term glucose monitoring throughout the world. The self-monitoring blood glucose (SMBG) is an approach through which people with or without diabetes can measure their blood sugar levels in their homes. Based on the reading, the patient can check the effects of their treatment such as diet, insulin, exercise, and stress management.

For a detailed analysis of the Global Point-of-Care Glucose Testing Market browse through-https://univdatos.com/report/point-of-care-glucose-testing-market/

GlobalPoint-of-Care Glucose Testing MarketSegmentation

Market Insight, by Product

Accu Check Aviva Meter

Onetouch Verio Flex

i-STAT

Freestyle Lite

Bayer CONTOUR Blood Glucose Monitoring System

True Metrix

Accu-Chek Inform II

StatStrip

Others

Market Insights, by End User

Hospitals

Home Settings

Others

Market Insight, by Region

North America

oU.S.

oCanada

oRest of North America

Europe

oGermany

oU.K.

oFrance

oSpain

oItaly

oRest of Europe

APAC

oChina

oJapan

oIndia

oRest of APAC

Rest of the World

Top Company Profiles

F. Hoffmann-La Roche Ltd

Abbott

Bayer AG

Nova Medical

ACON Laboratories, Inc.

Prodigy Diabetes Care, LLC

Trividia Health, Inc.

Nipro

EKF Diagnostics Holdings plc

Platinum Equity Advisors, LLC